These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10211132)

  • 1. A glutamatergic deficiency model of schizophrenia.
    Carlsson A; Hansson LO; Waters N; Carlsson ML
    Br J Psychiatry Suppl; 1999; (37):2-6. PubMed ID: 10211132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic aspects of schizophrenia.
    Tamminga C
    Br J Psychiatry Suppl; 1999; (37):12-5. PubMed ID: 10211134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examination of concurrent exposure to repeated stress and chlorpyrifos on cholinergic, glutamatergic, and monoamine neurotransmitter systems in rat forebrain regions.
    Pung T; Klein B; Blodgett D; Jortner B; Ehrich M
    Int J Toxicol; 2006; 25(1):65-80. PubMed ID: 16510359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-methyl-D-aspartate antagonists as drug models of schizophrenia: a surprising link to tobacco smoking.
    Domino EF; Mirzoyan D; Tsukada H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Aug; 28(5):801-11. PubMed ID: 15363604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoaminergic dysregulation in glutathione-deficient mice: possible relevance to schizophrenia?
    Jacobsen JP; Rodriguiz RM; Mørk A; Wetsel WC
    Neuroscience; 2005; 132(4):1055-72. PubMed ID: 15857710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between N-methyl-D-aspartic acid receptors and D1 dopamine receptors: an important mechanism for brain plasticity.
    Scott L; Aperia A
    Neuroscience; 2009 Jan; 158(1):62-6. PubMed ID: 19000746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Brain of patients with chronic schizophrenia and neurotransmitters].
    Toru M
    Seishin Shinkeigaku Zasshi; 2005; 107(10):1015-21. PubMed ID: 16381382
    [No Abstract]   [Full Text] [Related]  

  • 10. [Glutamatergic neurotransmission in schizophrenics].
    Bleich S; Bleich K; Wiltfang J; Maler JM; Kornhuber J
    Fortschr Neurol Psychiatr; 2001 Sep; 69 Suppl 2():S56-61. PubMed ID: 11533851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
    Gaspar PA; Bustamante ML; Silva H; Aboitiz F
    J Neurochem; 2009 Nov; 111(4):891-900. PubMed ID: 19686383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The acute effects of NMDA antagonism: from the rodent to the human brain.
    Gunduz-Bruce H
    Brain Res Rev; 2009 May; 60(2):279-86. PubMed ID: 18703087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic mechanisms in the pathogenesis of schizophrenia.
    Goldstein M; Deutch AY
    FASEB J; 1992 Apr; 6(7):2413-21. PubMed ID: 1348713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurocircuitries and neurotransmitter interactions in schizophrenia.
    Carlsson A
    Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():21-8. PubMed ID: 8866762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder.
    Woo TU; Walsh JP; Benes FM
    Arch Gen Psychiatry; 2004 Jul; 61(7):649-57. PubMed ID: 15237077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
    Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
    Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NR2A-containing NMDA receptors depress glutamatergic synaptic transmission and evoked-dopamine release in the mouse striatum.
    Schotanus SM; Chergui K
    J Neurochem; 2008 Aug; 106(4):1758-65. PubMed ID: 18540994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neural basis of psychosis-related behaviour in the infection model of schizophrenia.
    Meyer U; Feldon J
    Behav Brain Res; 2009 Dec; 204(2):322-34. PubMed ID: 19154759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Chloro-N-[(S)-phenyl [(2S)-piperidin-2-yl] methyl]-3-trifluoromethyl benzamide, monohydrochloride, an inhibitor of the glycine transporter type 1, increases evoked-dopamine release in the rat nucleus accumbens in vivo via an enhanced glutamatergic neurotransmission.
    Leonetti M; Desvignes C; Bougault I; Souilhac J; Oury-Donat F; Steinberg R
    Neuroscience; 2006; 137(2):555-64. PubMed ID: 16289893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.
    Heresco-Levy U
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1113-23. PubMed ID: 14642971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.